LoQus23 Therapeutics appoints Melanie Ivarsson as non-executive director
Article continues below
Dr. Ivarsson is a highly accomplished leader in the life sciences sector with more than 20 years of experience at pharmaceutical companies including Eli Lilly, Pfizer, Shire and Takeda, working across all phases of clinical drug development.
Dr. Ivarsson's work has included treatments for rare diseases such as hereditary angioedema (Takhzyro, Cinryze, Firazyr) and lysosomal storage disorders including Gaucher disease (VPriv), Hunter's syndrome (Elaprase) and Metachromatic leukodystrophy.
She is currently Chief Development Officer at Moderna, where she oversees the delivery of all clinical development programmes across the company's portfolio and led clinical trials to develop one of the world's first Covid-19 vaccines. ■